Astrocytes express dopamine receptors and respond to dopamine stimulation. However, the role of astrocytes in psychiatric disorders and the effects of antipsychotics on astroglial cells have only been investigated recently. S100B is a glial-derived protein, commonly used as a marker of astroglial activation in psychiatric disorders, particularly schizophrenia. We investigated S100B secretion in three different rat brain preparations (fresh hippocampal slices, C6 glioma cells and primary astrocyte cultures) exposed to apomorphine and antipsychotics (haloperidol and risperidone), aiming to evaluate, ex vivo and in vitro, whether dopamine activation and dopaminergic antagonists modulate astroglial activation, as measured by changes in the extracellular levels of S100B. The serum S100B elevation observed in schizophrenic patients is not reflected by the in vitro decrease of S100B secretion that we observed in hippocampal slices, cortical astrocytes and C6 glioma cells treated with apomorphine, which mimics dopaminergic hyperactivation. This decrease in S100B secretion can be explained by a stimulation of D2 receptors negatively coupled to adenyl cyclase. Antipsychotic medications and antioxidant supplementation were able to prevent the decline in S100B secretion. Findings reinforce the benefits of antioxidant therapy in psychiatric disorders. Based on our results, in hippocampal slices exposed to apomorphine, it may be suggested that antipsychotics could help to normalize S100B secretion by astrocytes.
Introduction
Schizophrenia is a chronic psychiatric disorder that affects approximately 1% of the population, and its positive symptoms (e.g., hallucinations and delusions) are correlated with elevated dopaminergic activity (Guillin et al., 2007) . The disruption of prepulse inhibition of the acoustic startle response by the dopamine agonist apomorphine in rats has been used in the last two decades as a model of schizophrenia-related disorders, and this disruption is reversed by both typical and atypical antipsychotic agents [e.g., (Mitchell and Neumaier, 2008; Swerdlow et al., 1994) ].
It is well known that astrocytes express dopamine receptors and respond to dopamine stimulation (Hertz et al., 1984) . However, the role of astrocytes in psychiatric disorders (De Keyser et al., 2008) and the effects of antipsychotics on astroglial cells have only been investigated recently (Quincozes-Santos et al., 2008; Roh et al., 2008) . S100B is a calcium-binding protein synthesized and secreted by astrocytes, and it is frequently used as a marker of astroglial activation (Donato et al., 2009; Goncalves et al., 2008) . However, its expression is not restricted to astrocytes in the brain (Steiner et al., 2007) or even to brain tissue (Goncalves et al., 2010) . Many groups (including ours) have reported S100B serum elevation in schizophrenic and bipolar patients (Andreazza et al., 2007; Lara et al., 2001 ). In schizophrenia, some studies have demonstrated increased S100B concentrations in the serum and cerebrospinal fluid (CSF), especially during acute stages of the disease (Rothermundt et al., 2001; Schroeter et al., 2003) . In addition, high S100B concentrations were associated with negative or deficit symptoms (Sarandol et al., 2007) with few exceptions (Schmitt et al., 2005) . More recently, a meta-analysis showed that serum S100B elevation is related to the exacerbation phase in schizophrenic patients .
Serum levels of S100B are elevated in untreated patients with schizophrenia, in comparison with healthy controls (Lara et al., 2001; Ling et al., 2007; Rothermundt et al., 2007) , but the effect of antipsychotic medication on S100B levels is still controversial. Increased (Ling et al., 2007; Qi et al., 2009; Schroeter and Steiner, 2009; Wiesmann et al., 1999) and decreased (Gattaz et al., 2000) levels of S100B were reported in medicated schizophrenic patients in comparison with healthy controls. Some in vitro studies have contributed to this question (Quincozes-Santos et al., 2008; Roh et al., 2008) . As such, it has been suggested that elevated levels of S100B in bodily fluids from schizophrenic patients are normalized rather than increased by antipsychotic drugs such as haloperidol or clozapine (Steiner et al., 2010b) . Despite these evidences, it is not clear whether serum S100B only reflects astroglial activation (Goncalves et al., 2010) , particularly in schizophrenic patients (Steiner et al., 2010c) .
Some S100B secretagogues in astroglial cells have been identified, including fluoxetin (Tramontina et al., 2008) , kainate (Sakatani et al., 2008) and carbenoxolone, an inhibitor of gap junctions ). In addition, two reports suggest a regulatory effect of antipsychotics on S100B secretion in C6 glioma cells and oligodendrocytic OLN-93 cells (Quincozes-Santos et al., 2008; Steiner et al., 2010b) , possibly mediated by dopamine receptors. Here we investigated S100B secretion in three different rat brain preparations (fresh hippocampal slices, C6 glioma cells and primary astrocyte cultures) exposed to apomorphine and antipsychotics (haloperidol and risperidone), aiming to evaluate ex vivo and in vitro whether dopamine activation and dopaminergic antagonists modulate astroglial activation measured as changes in the extracellular levels of S100B. S100B secretion is also affected by antioxidant compounds (Donato et al., 2009) , and apomorphine has protective effects on oxidative stress-induced cell death (Hara et al., 2006) . Therefore, we also investigated the effect of apomorphine together with other antioxidants on S100B secretion.
Methods

Animals
Thirty Wistar rats (twenty four male 30-day old rats for hippocampal slices and six 1 or 2-day old rats for cell culture) were obtained from our breeding colony (Department of Biochemistry, UFRGS, Porto Alegre, Brazil), were maintained under controlled light and environmental conditions (12 h light/12 h dark cycle at a constant temperature of 22 ± 1°C), and had free access to commercial chow and water. All animal experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised in 1996 and followed the regulations of the local animal housing authorities.
Chemicals
Poly-L-lysine, Dulbecco's modified Eagle's medium (DMEM), flasks and other material for cell culture, monoclonal anti-S100B antibody (SH-B1), 4-(2-hydroxyethyl)piperazene-1-ethanesulfonic acid (HEPES), Ophenylenediamine (OPD), [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT), apomorphine, N-acetylcysteine (NAC), and ascorbic acid (AA) were purchased from Sigma (St. Louis, MO, USA). Glutathione monoethylester (GSH) was obtained from Calbiochem (Darmstadt, Germany). Polyclonal Rabbit Anti-S100 was obtained from Dako (Glostrup, Denmark). Anti-rabbit IgG Horseradish Peroxidase was obtained from Amersham (Buckingamshire, UK). Fetal calf serum (FCS) was purchased from Gibco (Belo Horizonte, Brazil). Risperidone (Risperdal®) and haloperidol (Haldol®) were a gift from Janssen-Cilag (São Paulo, Brazil), a Brazilian division of Johnson & Johnson.
Hippocampal slice preparation
This procedure was carried out as described previously . Briefly, rats were decapitated, and their hippocampi quickly dissected out. Transverse sections (300 μm) were rapidly obtained with a McIlwain tissue chopper. One slice was placed into each well of a 24-well culture plate. Slices were incubated at room temperature in a HEPES-buffered saline solution (HBSS) containing (in mM): 120 NaCl; 2 KCl; 1 CaCl 2 ; 1 MgSO 4 ; 1 KH 2 PO 4 ; 10 glucose and 25 HEPES, pH 7.4. The medium was changed every 15 min with fresh medium. After a 120-min equilibration period, the slices were incubated for 1 h for S100B secretion assay at 30°C in the HBSS medium in the absence or presence of apomorphine (1, 10 or 100 μM); haloperidol, risperidone, Nacetylcysteine (NAC), glutathione monoethylester (GSH), and ascorbic acid were added to the incubation medium at the concentrations indicated in the Results section. Ten microliters of medium were collected for S100B measurement.
Astrocyte culture
Primary cortical astrocyte cultures from Wistar rats were prepared as previously described (Gottfried et al., 2003) . All procedures were in accordance with the NIH guidelines for the care and use of laboratory animals and were approved by the ethical committee from the University (UFRGS, Porto Alegre, Brazil). Briefly, cortices of newborn Wistar rats (1-2 days old) were removed and mechanically dissociated in Ca 2+ and Mg
2+
-free balanced salt solution. The cortex was cleaned of meninges and mechanically dissociated by sequential passage through a Pasteur pipette. After centrifugation at 1000 rpm for 5 min, the pellet was resuspended in DMEM (pH 7.6) supplemented with 8.39 mM HEPES, 23.8 mM NaHCO 3 , 0.1% Fungizone®, 0.032% garamicine and 10% FCS. Cultures were maintained in DMEM containing 10% FCS in 5% CO 2 /95% air at 37°C and allowed to grow to confluence. The medium was replaced by DMEM without serum in the absence or presence of apomorphine, haloperidol or risperidone (at concentrations indicated in the Results section). After 1 or 24 h of incubation, aliquots of 50 µL of media were collected for S100B measurement.
C6 glioma cells
A rat glioblastoma cell line was obtained from the American Type Culture Collection (Rockville, Maryland, USA). Late passage cells (i.e., after at least 100 passages) were seeded in 24-well plates at densities of 10 4 cells/well and cultured in DMEM (pH 7.4) supplemented with 5% FCS, 2.5 mg/mL amphotericin B and 100 U/L gentamicin in 5% CO2/95% air at 37°C . When the cells reached confluence, the culture medium was replaced by DMEM without serum in the absence or presence of apomorphine, haloperidol or risperidone (at concentrations indicated in the Results section). After 1 or 24 h of incubation, aliquots of 50 µL of media were collected for S100B measurement.
ELISA for S100B
The S100B concentration was measured as described previously . Briefly, 50 μL of sample plus 50 μL of Tris buffer were incubated for 2 h in a microtiter plate previously coated with monoclonal anti-S100B. Polyclonal anti-S100 was incubated for 30 min, and then peroxidase-conjugated anti-rabbit antibody was added for a further 30 min. The color reaction with o-phenylenediamine was measured at 492 nm. The standard S100B curve ranged from 0.002 to 1 ng/mL.
MTT reduction assay
Viability was assayed via the colorimetric MTT method (Hansen et al., 1989) . Briefly, the cells or slices were incubated with 0.5 mg/mL MTT followed by incubation in 5%CO 2 /95% air at 37°C or at 30°C for 30 min, respectively. The formazan product generated during the incubation was solubilized in dimethyl sulfoxide (DMSO) . Absorbance values were measured at 560 and 630 nm. The results are expressed as a percentage of the control.
Lactate dehydrogenase (LDH) release
LDH activity in the incubation medium was determined by a colorimetric commercial kit (from Doles, Brazil) according to the manufacturer's instructions.
Statistical analysis
Data are reported as the mean ± SEM and were analyzed by oneway analysis of variance (ANOVA) followed by Duncan's test or by Student's t test when indicated in the Results section and performed in SPSS-16.0. Values of p b 0.05 were considered significant.
Results
A curve of the effect of apomorphine from 1 to 100 μM on S100B release is shown in Fig. 1A . We found a significant effect of apomorphine (one-way ANOVA, F 3, 39 =8.254; pb 0.001). A post-hoc Duncan multiple range test showed that, at 100 μM, apomorphine was able to decrease S100B release in acute hippocampal slices (p b 0.05, compared to all the other groups). A decreasing trend was observed with apomorphine at 10 μM (pN 0.05). Two assays were performed in parallel to evaluate cell integrity and viability: LDH release (data not shown) and MTT reduction (Fig. 1B) , respectively; these results allow S100B release to be referred to more appropriately as S100B secretion.
At 100 μM apomorphine was also able to reduce S100B secretion by primary astrocytes and C6 glioma cells (Fig. 2) . In astrocyte cultures, this effect was observed at 1 h (Student's t test, p = 0.024) and 24 h after apomorphine addition (p = 0.045) ( Fig. 2A and B, respectively) .
Unfortunately, in our C6 cell preparations, we only found measurable extracellular levels of S100B at 24 h (p= 0.015) (Fig. 2B) .
The effects of antipsychotics on S100B secretion were evaluated in acute hippocampal slices (Fig. 3A) . At 10 μM, neither haloperidol nor risperidone were able to alter basal S100B secretion per se (F 2, 30 =0.915; p=0.411). However, in the presence of apomorphine, risperidone (F 2, 17 =5.758; p=0.012), but not haloperidol (F 2, 17 =1.971; p =0.170) increased S100B secretion when compared to haloperidol alone, but the level was not different from basal S100B secretion. The effects of the antipsychotics were also investigated in astrocyte and C6 cell cultures (Fig. 3B) . In primary astrocytes, no effect of either haloperidol or risperidone was observed on S100B secretion at 24 h. However, haloperidol (but not risperidone) decreased S100B secretion at 1 h (one-way ANOVA, pb 0.05; data not shown). Conversely, risperidone (but not haloperidol) was able to induce an increase of S100B secretion (oneway ANOVA, F 2, 24 =16.703; p b 0.001) in C6 cell cultures.
To investigate whether the S100B decrease induced by apomorphine was related to its ability to counteract oxidative stress, we investigated this effect in acute hippocampal slices treated with other antioxidant compounds: glutathione (GSH), N-acetyl-cysteine (NAC) and ascorbic acid (AA) (Fig. 4A) . Interestingly, GSH (but not NAC or AA) induced an increase in S100B secretion (one-way ANOVA, F 3,19 = 12.792; p b 0.001). However, all antioxidant compounds (in the presence of 100 μM apomorphine) were able to restore basal levels of S100B secretion. Moreover, because some antipsychotics appear to block certain oxidative stress signals, we performed co-incubations of the antipsychotics with glutathione (Fig. 4B) . Haloperidol switched off GSHinduced S100B secretion (Student's t test, p = 0.850), but risperidone was able to maintain this effect (p= 0.017). Fig. 1 . S100B secretion is negatively modulated by apomorphine in acute hippocampal slices. In A, S100B was released from hippocampal slices incubated with apomorphine (at indicated concentrations) for 60 min. S100B was measured by ELISA. Each value is the mean (± standard error) of six independent experiments performed in triplicate. * significantly different from respective basal S100B secretion, taken as 100% (one-way ANOVA followed by Duncan's test; pb 0.05). In B, an MTT reduction assay in hippocampal slices incubated with apomorphine (at the indicated concentrations) for 60 min. Each value is the mean (± standard error) of six independent experiments performed in triplicate.
Fig. 2. Apomorphine decreases S100B secretion in astrocytes and C6 glioma cells. S100B secretion at 1 h (in panel A) and 24 h (in panel B) in primary astrocyte cultures (open bars)
and in C6 glioma cells (gray bars) incubated in serum-free medium containing 100 μM apomorphine. S100B was measured by ELISA. Each value is the mean (± standard error) of six independent experiments performed in triplicate. * significantly different from respective basal S100B secretion (without apomorphine) (Student's t test; p b 0.05). ND (not detected) means that neither basal nor apomorphine-modulated S100B secretion was detected at 1 h in C6 cell preparations.
Discussion
Apomorphine is able to activate both D1-and D2-like receptors. These receptors apparently have opposing effects on signaling molecules such as cAMP (i.e., D1 activation increases cAMP while D2 decreases cAMP). An electrophysiological study on cortical slices suggested that D1 and D2 are activated at dopamine concentrations higher than 0.5 μM, and that D2 activation overrides D1 activation (Trantham-Davidson et al., 2004) . Moreover, D2 receptors are strongly expressed in astrocytes (Khan et al., 2001) . Therefore, astrocytes could be important targets of D2 antagonists and typical antipsychotics, and they may be involved in the pathogenesis of schizophrenia.
Here we found that apomorphine at 100 μM was able to reduce S100B secretion in hippocampal slices, primary cortical astrocytes and C6 glioma cells. Assuming that D2 receptors in astrocytes of these preparations are negatively coupled to adenyl cyclase, a decrease in S100B secretion would be an expected result. Other results with forskolin, fluoxetin and serotonin suggest a connection between cAMP and S100B secretion (Goncalves et al., 2002; Tramontina et al., 2008) .
In schizophrenic patients, dopaminergic hyperactivation has been proposed to underlie the exacerbation of positive symptoms, which is where typical antipsychotics are most effective. Therefore, ignoring the effects of other S100B secretagogues on astrocytes, a decrease of S100B secretion would be expected from these cells in schizophrenic patients. Conversely, increased serum S100B has been observed in schizophrenic patients in multiple studies (Lara et al., 2001; Rothermundt et al., 2004; ). However, it remains unclear whether elevated serum S100B specifically reflects astroglial activation. In fact, extra-cerebral sources can contribute to serum S100B, particularly adipocytes (Goncalves et al., 2010) . Moreover, recent findings strongly suggest that S100B levels in the blood correlate with adipose tissue in normal individuals (Steiner et al., 2010a) and with insulin resistance in schizophrenic patients (Steiner et al., 2010c) . Our data therefore suggest that the serum S100B elevation observed in schizophrenic patients is not necessarily due to astroglial activation by dopaminergic hyperactivation. Other cell sources of S100B and/or other S100B secretagogues must be involved in that elevation.
Moreover, the effect of antipsychotics on peripheral S100B in schizophrenic patients is also a matter of controversy. In fact, clinical studies have shown both increases (Qi et al., 2009; Schmitt et al., 2005; Schroeter et al., 2003; Wiesmann et al., 1999) and decreases (Gattaz et al., 2000; Ling et al., 2007; Steiner et al., 2009 ) of blood S100B that could be related to antipsychotic medication. Two previous studies addressed this question by investigating the in vitro effect of antipsychotics on S100B secretion in glial cells. C6 glioma cells treated with risperidone (10-40 μM) exhibited an increase of S100B secretion (Quincozes-Santos et al., 2008) , whereas C6 glioma cells and oligodendrocytic OLN-93 cells treated with haloperidol (1 μg/mL or 2.7 μM) or clozapine (10 μg/mL or 30 μM) exhibited a decrease in S100B secretion Fig. 3 . Antipsychotics prevent the apomorphine-induced decrease of S100B secretion. In A, S100B secretion at 1 h in acute hippocampal slices in the presence or absence of apomorphine (at 100 μM) and exposed to antipsychotics (haloperidol or risperidone at 10 μM). S100B was measured by ELISA. Each value is the mean (± standard error) of six independent experiments performed in triplicate. * significant difference between risperidone groups in the presence and absence of apomorphine (one-way ANOVA followed by Duncan's test; p b 0.05). However, none of the antipsychotics differed from basal secretion. In B, primary astrocyte cultures (open bars) or C6 glioma cells (gray bars) incubated in serum-free medium containing haloperidol or risperidone at 10 μM. Each value is the mean (± standard error) of six independent experiments performed in triplicate. Extracellular S100B at 24 h was measured by ELISA * significantly different from respective basal S100B secretion (one-way ANOVA followed by Duncan's test; p b 0.05). Fig. 4 . Antioxidants also prevent the apomorphine-induced decrease of S100B secretion. In A, S100B secretion at 1 h in acute hippocampal slices in the presence or absence of apomorphine (at 100 μM) and exposed to antioxidants (NAC, N-acetyl-cysteine; GSH, glutathione monoethylester; or AA, ascorbic acid, all at 100 μM). Extracellular S100B was measured by ELISA. Each value is the mean (± standard error) of six independent experiments performed in triplicate. * significantly different from basal S100B secretion (one-way ANOVA followed by Duncan's test; p b 0.05). In B, S100B secretion at 1 h in acute hippocampal slices in the presence of GSH (at 100 μM) and haloperidol or risperidone (at 10 μM). Extracellular S100B was measured by ELISA. Each value is the mean (± standard error) of six independent experiments performed in triplicate. * significantly different from basal S100B secretion (Student's t test; p b 0.05). (Steiner et al., 2010b) . This apparent discrepancy on S100B secretion could be due to differences in multiple conditions (drugs, concentrations, serum-containing medium, cell types and metabolic conditions). Under our conditions, neither haloperidol nor risperidone (both at 10 μM) affected basal S100B secretion in two investigated preparations, hippocampal slices (1 h) and cortical astrocyte cultures (24 h), but we observed an increase in S100B secretion (24 h) in C6 glioma cells treated with riperidone. Interestingly, a transitory decrease of S100B secretion (1 h) was observed in astrocyte cultures exposed to haloperidol. Although C6 cells and astrocytes have been assumed indistinctly to be astroglial cells, many discrepancies between them have been observed [e.g., ], and these could partially explain our results. For instance, concerning dopaminergic communication, dopamine stimulation is able to up-regulate glutathione in astrocytes but not in C6 glioma cells (Han et al., 1996) .
It is quite difficult to project our in vitro S100B secretion results with astrocyte preparations and brain slices onto the changes in peripheral S100B that occur in schizophrenic patients under long-term medication. However, based on our results in hippocampal slices exposed to apomorphine, it is possible to speculate that antipsychotics help to normalize S100B secretion by astrocytes, as previously suggested by Steiner's group (Steiner et al., 2010b) . However, it is not clear whether this is mediated by dopamine or another neurotransmitter receptor.
Due to the protective effect of antipsychotic medications against oxidative stress, we decided to investigate the effect of classical antioxidants (NAC, glutathione and ascorbic acid) on the S100B secretion decrease induced by apomorphine in hippocampal slices. All of the antioxidants were able to normalize S100B secretion, but glutathione was also able to induce an increase of S100B secretion. This aspect is very interesting because glutathione is not only a free radical scavenger but is also exported by astrocytes. This compound has extracellular activity on some ion channels and G protein-coupled receptors (Wang et al., 2006) , and this could directly or indirectly modulate S100B secretion, the mechanism of which remains unknown (Donato et al., 2009) . Note that haloperidol, but not risperidone, somehow affected this glutathioneinduced S100B secretion. This reinforces the idea that typical antipsychotics such as haloperidol might aggravate the oxidative stress observed in schizophrenic patients (Ng et al., 2008; Pillai et al., 2007) . Nevertheless, our data support the idea that antioxidant therapy is useful for preventing some neurochemical alterations in schizophrenia, particularly astroglial S100B secretion, even taking into account all of the limitations of this in vitro study associated with using apomorphine to induce dopaminergic hyperactivation.
It is important to mention some limitations of this study. First, we examined S100B secretion in hippocampal slices, but other brain regions, e.g. prefrontal cortex, deserve further investigation due to their importance in schizophrenia [e.g. (Artigas, 2010) ]. Secondly, we focused our discussion about schizophrenia based on alterations in dopaminergic neurotransmission. However, other hypotheses must be considered, particularly those based on altered glutamatergic communication. In fact, an intricate linkage between glutamatergic and dopaminergic systems offers a wide comprehension about schizophrenia alterations, including oxidative stress. The glutamatergic hypothesis for schizophrenia, for example, suggests that NMDA receptor hypofunction leads to an increased glutamatergic transmission in the prefrontal cortex (GunduzBruce, 2009 ). In support of this, we found that elevated levels of glutamate, like apomorphine, decreased S100B secretion Tramontina et al., 2006) . However, as discussed before, this decrease in secretion contrasts with the serum S100B elevation observed in schizophrenic patients, possibly because extracerebral sources contribute to serum S100B (Goncalves et al., 2010; Steiner et al., 2010a Steiner et al., , 2010c . Thirdly, the effect of risperidone is not limited to receptors of dopamine, and serotonin receptors are possibly involved in the observed effects. This aspect helps to explain some differences observed with haloperidol and risperidone, in agreement with previous studies (Quincozes-Santos et al., 2008) .
Conclusions
Our data on astroglial S100B secretion were analyzed in light of the potential use of S100B as a marker of astroglial activation in psychiatric disorders, particularly schizophrenia. However, the serum S100B elevation observed in schizophrenic patients does not fit with the in vitro decrease of S100B secretion we observed in hippocampal slices, cortical astrocytes and C6 glioma cells treated with apomorphine, which mimics dopaminergic hyperactivation. This decrease of S100B secretion can be explained by the stimulation of D2 receptors negatively coupled to adenyl cyclase. Antipsychotic medication and antioxidant supplementation were able to prevent the decline in S100B secretion. This reinforces the benefits of antioxidant therapy in psychiatric disorders. Moreover, our data suggest that more caution should be exercised when interpreting changes in peripheral S100B levels as a sign of astroglial activation, particularly considering the extra-cerebral sources of this protein.
